Abstract: SA-PO559
Machine Perfusion of Mice Kidneys to Deliver a Protective Bioengineered Soluble ACE2 Protein
Session Information
- Bioengineering
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bioengineering
- 400 Bioengineering
Authors
- Cianfarini, Cosimo, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Yamani, Fatmah Najeeb, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Wysocki, Jan, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Jaishankar, Dinesh, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Zhang, Zheng Jenny, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Batlle, Daniel, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Background
Machine perfusion of donor kidneys has emerged as a promising approach to improve transplant outcomes by decreasing storage-related injury and reducing the occurrence of delayed graft function (DGF). Activation of the renin-angiotensin-system (RAS) has been shown to play a role in the pathophysiology of DGF and countering this overactivity may improve transplant outcomes. Here we investigated the delivery of a short soluble ACE2 protein, bioengineered in our lab and termed ACE2-618-ABD, to mice kidneys using hypothermic machine perfusion as a strategy to reduce RAS activity.
Methods
Kidneys from c57bl6 ACE2 Knock-Out (ACE2-KO) and c57bl6 wildtype (WT) mice were harvested and the renal artery cannulated. We adapted a perfusion system previously used for rats to be used with mice kidneys. The mice kidneys were perfused with phosphate buffered saline (PBS) either alone or with added ACE2 618-ABD for four hours at four degrees celsius through the cannulated renal artery in a closed-circuit perfusion system using a peristaltic pump. ACE2 enzymatic activity was then measured using a fluorogenic assay and ACE2 protein levels determined by Western Blot.
Results
While ACE2 enzymatic activity and protein were undetectable in non-perfused ACE2-KO kidneys, enzymatic activity and protein by Western Blot were found in ACE2-618-ABD perfused ACE2-KO kidneys. In WT kidneys perfused with ACE2-618-ABD, Western Blot showed two distinct bands for ACE2 protein at ~100kD and ~85kD. The ~100kD band reflects the native ACE2, the ~85kD represents the perfused short soluble ACE2-618-ABD which was not found in the PBS- and non-perfused WT kidneys. In kidney lysates, the cytosolic compartment of ACE2-618-ABD perfused kidneys had increased ACE2 enzymatic activity and protein demonstrating intracellular uptake.
Conclusion
Delivery of a bioengineered, short soluble ACE2 protein to mice kidneys can be accomplished via machine perfusion of the renal artery which results in passage of the glomerular filtration barrier and tubular uptake. Ex-vivo perfusion of kidneys with ACE2-618-ABD results in cytosolic uptake as demonstrated by increased protein and enzymatic activity. This approach may result in improved quality of kidneys prior to transplantation.
Funding
- Other NIH Support